Single Dose Study Of GW856553 On A Protein That Is An Indicator For Rheumatoid Arthritis (RA)

Phase 2

Completed

• Conditions: Arthritis, Rheumatoid

• Registration Number: NCT00256919
• Lead Sponsor: GlaxoSmithKline

Brief Summary

This study is designed to compare a range of doses of GW856553 versus placebo on the biomarkers associated with rheumatoid arthritis

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2005-11
• Study First Submitted: 2005-11-21
• Study First Submitted QC: 2005-11-21
• Study First Posted: 2005-11-22
• Primary Completion: 2006-11
• Study Completion: 2006-11
• Status Verified: 2012-10
• Last Update Submitted: 2012-11-01
• Last Update Posted: 2012-11-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
C-reactive protein (CRP) levels 72 hours post-dose.	72 hours post-dose.

Secondary Outcome Measures

Name	Time	Method
C-reactive protein (CRP) levels 24 and 48 hours post-dose	24 and 48 hours post-dose

Trial Locations

Locations (1)

GSK Investigational Site; 🇺🇦 Lviv, Ukraine